Sanofi Stock Screener | Share Price & Fundamental Analysis
SANOFI
Pharmaceuticals
Screen Sanofi share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹4172.50
▼
-18.70 (-0.45%)
Share Price BSE
₹4178.55
▼
-12.10 (-0.29%)
Market Cap
₹9,446.70 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
10.95
EPS (TTM)
₹179.46
Dividend Yield
2.85%
Debt to Equity
0.02
52W High
₹6569.50
52W Low
₹4057.00
Operating Margin
32.00%
Profit Margin
22.26%
Revenue (TTM)
₹539.00
EBITDA
₹175.00
Net Income
₹120.00
Total Assets
₹1,612.00
Total Equity
₹861.00
Sanofi Share Price History - Stock Screener Chart
Screen SANOFI historical share price movements with interactive charts. Analyze price trends and patterns.
Sanofi Company Profile - Fundamental Screener
Screen Sanofi company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SANOFI shares.
Sanofi India Limited is a pharmaceutical company primarily engaged in manufacturing and trading drugs and pharmaceuticals. It operates manufacturing facilities in Goa and Ankleshwar, Gujarat, and sells products through independent distributors mainly in India. The company focuses on five therapeutic areas: diabetes, epilepsy, cardiology, allergy, and pain care. Key products include Lantus (insulin), Combiflam (pain relief), Amaryl (anti-diabetic), Allegra (allergy), Cardace (cardiovascular), and Toujeo (long-acting insulin). Sanofi India is majority-owned by Sanofi and its subsidiary Hoechst GmbH, holding 60.37% of its paid-up share capital. The company has undergone several name changes and acquisitions, including the purchase of Universal Medicare's nutraceutical business in 2011. In 2021, Sanofi India sold its Nutraceuticals business to Universal Nutriscience Private Limited, and in 2022-23, its Consumer Healthcare Business was demerged into a wholly-owned subsidiary.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Aditya Narayan
ISIN
INE058A01010
Website
https://www.sanofiindialtd.com
Sanofi Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen SANOFI balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2024 | 2023 |
|---|---|---|
| Assets | ||
| Total Assets | 1,612 | 1,715 |
| Current Assets | 1,127 | 1,248 |
| Fixed Assets | 313 | 315 |
| Liabilities | ||
| Total Liabilities | 1,612 | 1,715 |
| Current Liabilities | 32 | 48 |
| Non-Current Liabilities | 0 | 0 |
| Shareholders' Equity | ||
| Total Equity | 861 | 1,015 |
| Share Capital | 23 | 23 |
| Reserves & Surplus | 838 | 992 |
Screen SANOFI income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 539 | 529 | 526 | 503 | 579 | 547 | 573 | 572 | 622 |
| Expenses | 364 | 397 | 404 | 367 | 400 | 370 | 377 | 393 | 368 |
| EBITDA | 175 | 132 | 122 | 137 | 179 | 177 | 195 | 179 | 254 |
| Operating Profit % | 32.00% | 23.00% | 23.00% | 21.00% | 22.00% | 21.00% | 23.00% | 24.00% | 29.00% |
| Depreciation | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Profit Before Tax | 165 | 122 | 113 | 127 | 169 | 167 | 186 | 169 | 244 |
| Tax | 46 | 31 | 30 | 24 | 33 | 30 | 34 | 46 | 54 |
| Net Profit | 120 | 91 | 82 | 103 | 137 | 138 | 152 | 123 | 190 |
| EPS | 51.89 | 39.64 | 35.69 | 44.81 | 59.31 | 59.79 | 65.95 | 53.37 | 82.78 |
Sanofi Cash Flow Screener - Liquidity Fundamentals
Screen SANOFI cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2024-March | 2023-March |
|---|---|---|
| Operating Activities | 462 | 230 |
| Investing Activities | -180 | 38 |
| Financing Activities | -392 | -878 |
| Net Cash Flow | -111 | -610 |
Screen SANOFI shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% |
| FII Holding | 5.57% | 5.61% | 5.57% | 6.11% | 5.81% | 5.78% | 5.63% | 0.00% |
| DII Holding | 23.02% | 23.06% | 22.29% | 23.08% | 22.79% | 22.82% | 22.93% | 19.47% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 8.38% | 8.33% | 9.08% | 7.97% | 8.31% | 8.21% | 8.33% | 9.29% |
| Other Holding | 2.63% | 2.61% | 2.67% | 2.44% | 2.69% | 2.79% | 2.70% | 10.85% |
| Shareholder Count | 68,196 | 66,790 | 71,395 | 61,849 | 67,662 | 66,211 | 66,401 | 76,694 |
Sanofi Dividend Screener - Share Yield Analysis
Screen SANOFI dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹117.00 | 2.04% |
| 2023-March | ₹167.00 | 2.06% |
| 2022-March | ₹570.00 | 10.15% |
| 2021-March | ₹490.00 | 6.53% |
| 2020-March | ₹365.00 | 4.63% |
| 2019-March | ₹349.00 | 5.58% |
| 2018-March | ₹84.00 | 1.44% |
| 2017-March | ₹71.00 | 1.37% |
Sanofi Index Membership - Market Screener Classification
Screen SANOFI by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Sanofi Market Events Screener - Corporate Actions
Screen SANOFI market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-07 | 2025-11-07 | Dividend | ₹ 75.00 /share | -0.03% |
| 2025-10-29 | 2025-10-29 | Quarterly Result Announcement | NA | -0.56% |
| 2025-07-31 | 2025-07-31 | Quarterly Result Announcement | NA | -1.24% |
| 2025-05-15 | 2025-05-15 | Annual General Meeting | NA | 8.52% |
| 2025-05-14 | 2025-05-14 | Quarterly Result Announcement | NA | 3.02% |
| 2025-04-25 | 2025-04-25 | Dividend | ₹ 117.00 /share | 29.86% |
| 2025-02-27 | 2025-02-27 | Quarterly Result Announcement | NA | -5.58% |
| 2024-11-07 | 2024-11-07 | Quarterly Result Announcement | NA | -6.28% |
| 2024-05-14 | 2024-05-14 | Annual General Meeting | NA | -13.18% |
| 2024-05-03 | 2024-05-03 | Dividend | ₹ 117.00 /share | -5.75% |
| 2024-03-07 | 2024-03-07 | Dividend | ₹ 50.00 /share | -7.37% |
| 2023-12-18 | 2023-12-18 | Extraordinary General Meeting | NA | 3.21% |
| 2023-05-11 | 2023-05-11 | Annual General Meeting | NA | 5.58% |
| 2023-04-28 | 2023-04-29 | Dividend | ₹ 183.00 /share | 3.20% |
| 2023-04-28 | 2023-04-29 | Dividend | ₹ 194.00 /share | 3.20% |
Sanofi Competitors Screener - Peer Comparison
Screen SANOFI competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 413,981 | 39.37 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,254 | 67.76 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,251 | 60.85 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,731 | 22.30 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 103,678 | 18.24 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,220 | 22.10 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 91,940 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,818 | 50.34 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,929 | 20.25 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,498 | 27.11 | 13,458 | 3.70% | 2,216 | 38.49 |
Sanofi Company Announcements - News Screener
Screen SANOFI latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-05 | Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015 | View |
| 2026-01-01 | Closure of Trading Window | View |
| 2026-01-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-12-30 | Please Find Enclosed Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-12-28 | Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015 | View |
| 2025-12-20 | Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-12-18 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | View |
| 2025-12-18 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | View |
| 2025-11-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-17 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | View |
| 2025-11-04 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-10-31 | Intimation Of Record Date | View |
| 2025-10-30 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-10-30 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-10-29 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-10-29 | Announcement under Regulation 30 (LODR)-Dividend Updates | View |
| 2025-10-29 | Financial Results For The Quarter And Nine Months Ended 30Th September 2025 | View |
| 2025-10-29 | Board Meeting Outcome for Financials Results For The Quarter Ended 30Th September 2025 And Recommendation Of Interim Dividend | View |
| 2025-10-27 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-10-27 | Announcement under Regulation 30 (LODR)-Cessation | View |